Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2005

View Archived Issues

Gabexate mesilate tested for therapeutic potential in gut hypoperfusion

MG-132 modulates cytokine response and mortality in preclinical sepsis model

Protective effects of green tea polyphenols against acetaminophen-induced liver damage

Novasome delivery of H2 antagonists shows promise for periodontal disease

Pharmacokinetics and tissue distribution of fumitremorgin C in tumor-bearing mice

Icos and Solvay to copromote AndroGel

Priority review for Tygacil NDA

YM Biosciences and Shin Poong Pharmaceutical partner for tesmilifene

Neose and BioGeneriX enter option agreement for GlycoPEGylation technology

Access updates recent developments

Lilly withdraws duloxetine NDA for stress urinary incontinence

Enrollment begins in phase II study of MS-I.E.T.

Northwest to begin phase III trial of DCVax-Prostate

New indications approved for Neoral and Sandimmun in Japan

Preclinical targeting of B-cell lymphoma using the humanized monoclonal antibody CMC-544

Aromatization reported to increase the cognitive benefits of testosterone supplementation

Phase II data on the benefits of Acclaim in chronic stable angina

Antirheumatic effects of MMP inhibitor in adjuvant-induced arthritis model

Chronic blockade of ETB receptors exacerbates degeneration of cardiomyocytes

Ajinomoto patents TRPV receptor ligands for treatment of pain

New compounds for immune-mediated diseases designed at Merck

OSI scientists develop new glycogen phosphorylase inhibitors

Integrin antagonists in early development at Genentech

Calcium channel blockers emerge from NeuroMed R&D

Guilford discloses new PARP inhibitors

RDP-58 active in model of interstitial cystitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...